# Nuclide record f-dosimetry (section). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/fronts/f-dosimetry/>
  a schema:DefinedTerm ;
  nuclide:kind "section" ;
  schema:identifier "f-dosimetry" ;
  schema:name "Dosimetry"@en ;
  schema:description "Dosimetry works out exactly how much radiation dose a patient's tumour and healthy organs actually receive, so treatment can in principle be tailored to the person rather than given as one fixed dose to everyone."@en ;
  schema:url <https://nuclide.cc/fronts/f-dosimetry/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://eanm.org/wp-content/uploads/2025/02/EANM-Reply-to-the-public-consultation-on-the-European-Medicines-Agency-Concept-paper-on-clinical-evaluation-of-therapeutic-radiopharmaceuticals-in-oncology.pdf>, <https://www.onclive.com/view/personalized-radioembolization-improves-os-vs-standard-dosing-in-advanced-hcc>, <https://eanm.org/publications/guidelines/overview/dosimetry/> ;
  nuclide:related <https://nuclide.cc/fronts/f-radioligand-therapy/>, <https://nuclide.cc/fronts/f-radioembolisation/>, <https://nuclide.cc/fronts/f-regulation-reimbursement/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/y-90/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/hcc/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-dosimetry/>, <https://nuclide.cc/technologies/in-vivo-dosimetry/>, <https://nuclide.cc/technologies/quantitative-imaging-biomarkers/> ;
  nuclide:institutions <https://nuclide.cc/institutions/eanm/>, <https://nuclide.cc/institutions/snmmi/> ;
  nuclide:terms <https://nuclide.cc/terms/dosimetry/>, <https://nuclide.cc/terms/gray-unit/> .